Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DM1 +/- Temozolomide for HER2+ Breast Cancer Brain Metastases
NCT03190967Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Apr 2018
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of temozolomide in brain metastases (3 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose of Temozolomide at 21 days and Median Amount of Time Participant Survives Without New Brain Lesions. Started Apr 2018; status: terminated.
02
Drugs
temozolomide
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT03190967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03190967.